COMMUNIQUÉS West-GlobeNewswire
-
Oxurion NV to present further scientific findings supporting therapeutic potential of THR-317 & THR-687 as promising new therapies for Diabetic Eye Disease at upcoming EURETINA 2018 in Vienna, Austria
17/09/2018 - 17:41 -
Nesvik Pharmaceuticals, Inc., a Subsidiary of BioStem Technologies, Inc., Announces Engagement of The Gnomon Group for Pre-Investigational New Drug Application Strategy
17/09/2018 - 16:43 -
Advanzeon Solutions Engages Hayden IR to Develop Comprehensive Investor Relations Program
17/09/2018 - 16:38 -
CLS Holdings USA Executes Two Letters of Intent, which will provide the Opportunity to Enter the Rapidly Expanding Massachusetts Market
17/09/2018 - 15:38 -
Phase 2 Ready Oncology Drug Receives FDA Orphan Drug Designation
17/09/2018 - 15:28 -
Medtronic Joins Catalyst CEO Champions For Change and Pledges to Accelerate Women Into Management and Board Seats
17/09/2018 - 15:16 -
ATW Tech Signs a Letter of Intent for the Divestiture of Its Atman Assets
17/09/2018 - 15:00 -
ATW Tech signe une lettre d’intention pour la vente des actifs d’Atman
17/09/2018 - 15:00 -
Comprehensive Pharmacy Services Named Best Pharmacy Support Services Provider – USA
17/09/2018 - 15:00 -
Avadim Technologies Announces Name Change To Avadim Health, Inc.
17/09/2018 - 15:00 -
Transactions under Novozymes’ stock buyback program
17/09/2018 - 14:57 -
PSI’s Acquisition of KINEX Strengthens Company’s Position as an IT Leader
17/09/2018 - 14:56 -
GUERBET : Information sur les opération effectuées dans le cadre du programme de rachat d'actions
17/09/2018 - 14:43 -
Extendicare Announces September 2018 Dividend of C$0.04 per Share
17/09/2018 - 14:35 -
New Independent Data Further Demonstrates Clinical Utility of Daxor Corporation’s Blood Volume Analyzer (BVA-100) Over Surrogate Measurements
17/09/2018 - 14:30 -
Ultragenyx Expands Leadership Team and Appoints Dr. Wladimir Hogenhuis as Chief Operating Officer
17/09/2018 - 14:30 -
FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences’ CLR 131 for the Treatment of Osteosarcoma
17/09/2018 - 14:30 -
Menlo Therapeutics Begins European Prurigo Nodularis Phase 3 Trial and Presents Additional Data from PN Phase 2 Trial at EADV
17/09/2018 - 14:30 -
Novo Nordisk A/S - Share repurchase programme
17/09/2018 - 14:29
Pages